



Express Mail Certificate EV 517 992 900 US

PTO/SB/08A (07-06)

Approved for use through 09/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806 (MCG 003-03)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
WRG	1.	BASHEER, R. et al., "Adenosine as a biological signal mediating sleepiness following prolonged wakefulness," Biol. Signals Recept., 9(6): 319-327 (2000) (Abstract only)	
	2.	BONNER, JAMES A. et al., "Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck," New England Journal of Medicine, 354(6): 567-578 (2006)	
	3.	BROADDUS, V. COURTNEY et al., "Neutralization of IL-8 Inhibits Neutrophil Influx in a Rabbit Model of Endotoxin-Induced Pleurisy," Journal of Immunology, 152: 2960-2967 (1994)	
	4.	BURSILL, CHRISTINA A. et al., "Membrane-Bound CC Chemokine Inhibitor 35K Provides Localized Inhibition of CC Chemokine Activity in Vitro and in Vivo," The Journal of Immunology, 177: 5567-5573 (2006)	
	5.	CASILLI, FEDERICA et al., "Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2," Biochemical Pharmacology, 69: 385-394 (2005)	
	6.	COIFFIER, BERTRAND, "Monoclonal antibody as therapy for malignant lymphomas," C.R. Biologies, 329: 241-254 (2008)	
	7.	CUNNINGHAM, M.D., DAVID et al., "Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer," New England Journal of Medicine, 351: 337-345 (2004)	
	8.	DIEU, MARIE-CAROLINE et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med., 188: 373-386 (1998)	
	9.	FELOMANN, MARC and RAVINDER N. MAINI, "Anti-TNF $\alpha$ Therapy of Rheumatoid Arthritis: What Have We Learned?," Annu. Rev. Immunol., 19: 163-196 (2001)	
	10.	HART, T. K. et al., "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma," Clin. Exp. Immunol., 130: 93-100 (2002)	
	11.	KAMINSKI, MARK S. et al., "Radioimmunotherapy of B-Cell Lymphoma with [ <sup>131</sup> I] Anti-B1 (Anti-CD20) Antibody," New England Journal of Medicine, 329: 459-465 (1993)	
	12.	LIN, MICHAEL Z. et al., "The Evolution of Antibodies into Versatile Tumor-Targeting Agents," Clinical Cancer Research, 11: 129-139 (2005)	

Examiner Signature

Date Considered

3/22/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806 (MCG 003-03)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
[Signature]	13.	MUNN, DAVID H. et al., "Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes," The Journal of Clinical Investigation, 114(2): 280-290 (2004)	
	14.	MUNN, DAVID H. et al., "GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase," Immunity, 22: 633-642 (2005)	
	15.	PANDI-PERUMAL, S. R. et al., "Melatonin: Nature's most versatile biological signal?" FEBS Journal, 273: 2813-2838 (2006)	
	16.	PICCART-GEHART, M.D., Martine J. et al., "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer," New England Journal of Medicine, 353(16): 1659-1672 (2005)	
	17.	RAMCHANDANI, SHYAM et al., "DNA methylation is a reversible biological signal," Proc. Natl. Acad. Sci. USA, 96: 6107-6112 (1999)	
	18.	SLAMON, M.D., Dennis J. et al., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 For Metastatic Breast Cancer that Overexpresses HER2," New England Journal of Medicine, 344(11): 783-792 (2001)	
	19.	UNO, TOMOYASU et al., "Eradication of established tumors in mice by a combination antibody-based therapy," Nature Medicine, 12(6): 693-698 (2006)	
	20.	YANG, D. et al., "β-Defensins: Linking Innate and Adaptive Immunity Through Dendritic and T Cell CCR6," Science, 286: 525-528 (1999)	
	21.	YANG, JAMES C. et al., "A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer," New England Journal of Medicine, 349(5): 427-434 (2003)	
	22.	ZANGEMEISTER-WITTKKE, UWE, "Antibodies for Targeted Cancer Therapy- Technical Aspects and Clinical Perspectives," Pathobiology, 72: 279-286 (2005)	
[Signature]	23.	ZOU, WEIPING et al., "Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells," Nature Medicine, 7(12): 1339-1346 (2001)	

Examiner  
SignatureDate  
Considered

3/17/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.